Quizartinib Improved Leukemia Survival Rates in Study
Adults with a specific genetic mutation saw better survival outcomes with one drug over another.
Updated on Oct. 1, 2026 in Cancer
A multicenter cohort study of 215 adults with newly diagnosed FLT3-ITD-mutated acute myeloid leukemia found that patients treated with quizartinib experienced higher survival rates than those treated with midostaurin. The study analyzed data across 12 U.S. centers.
Why it matters
This research provides comparative data on treatment efficacy and stability for a specific form of leukemia, offering insight into how different therapies perform when combined with intensive chemotherapy.
This multicenter cohort study compared quizartinib and midostaurin in 215 adults with newly diagnosed FLT3-ITD-mutated acute myeloid leukemia. Participants taking quizartinib saw a 93% 1-year overall survival rate compared to 78% for those on midostaurin.
The players
Acute Myeloid Leukemia
A complex type of blood cancer that originates in the bone marrow and requires intensive chemotherapy and targeted therapy.
The details
Researchers compared the outcomes of quizartinib and midostaurin when each was administered alongside 7+3 intensive induction chemotherapy. The study observed that the quizartinib group experienced significantly fewer treatment interruptions or delays at 11.4%, compared to 25.2% in the midostaurin cohort, suggesting potential differences in tolerability or administrative ease during the treatment regimen.
Timeline
Data were collected from patient treatments occurring between May 2017 and May 2025.
Health Landscape
The findings reflect a broader trend in oncology to refine and compare targeted therapies for specific genetic mutations in leukemia. This study adds to the work led by centers like the Leukemia Division to optimize the effectiveness of induction chemotherapy regimens.
Patients currently undergoing treatment or considering options for FLT3-ITD-mutated leukemia should discuss these comparative outcomes with their oncology team. It is essential to understand how specific treatment interruptions or delays might affect your individual care plan.
The takeaway
Targeted leukemia therapies vary in both survival impact and patient tolerance when used with chemotherapy. If you or a loved one are facing this diagnosis, ask your doctor about the relative risks of treatment delays and how specific drug combinations may influence your personalized care.
Further reading
For more information on current treatment standards, visit the Cancer section of our site.
Source note: This article includes information reported by Pharmacytimes.
